EGFR and neoplasm: Such findings were seen in a prior analysis of [18F]2-fluoro-2-deoxy-d-glucose–positron emission tomography scan to assess tumor burden in EGFR+ aNSCLC,31 which suggested that the reliable systemic effect from highly effective targeted therapies may overcome otherwise poor prognosis, though additional follow-up is needed to understand if TF impacts the eventual pattern and biology of resistance.